Skip to main content

ozanimod

Generic: OZANIMOD HYDROCHLORIDE·Brand: ZEPOSIA, Zeposia

ozanimod: 5 clinical trials tracked.

ozanimod evidence translation

What we can confirm

5 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about ozanimod, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 2 study sponsors
Clinical Trials (5)

Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia

Recruiting

Primary endpoint: Proportion of progressive multifocal leukoencephalopathy (PML) cases by participant characteristics and potential risk factors among ozanimod-exposed participants with multiple sclerosis

Observational15 targetStarted 2026-06Completion 2041-071 site · United StatesBristol-Myers Squibb

Real-world Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis: A Chart Review Study

Recruiting

Primary endpoint: Proportion of participants achieving steroid-free symptomatic remission

Observational150 targetStarted 2026-01Completion 2027-1217 sites · JapanBristol-Myers Squibb

A Phase 3, Multicenter, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

NCT06408259·Phase 3·BMY
Recruiting

Primary endpoint: Annualized relapse rate (ARR)

InterventionalRandomizedquadruple194 targetStarted 2025-04Completion 2036-0733 sites · Australia, Italy, Mexico, Poland…Bristol-Myers Squibb

A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy

NCT05076175·Phase 2/Phase 3·BMY
Recruiting

Primary endpoint: Proportion of participants who achieve clinical remission

InterventionalRandomizedquadruple120 targetStarted 2022-05Completion 2032-0750 sites · Australia, Belgium, Canada, France…Bristol-Myers Squibb

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Active, not recruiting

Primary endpoint: Number of Major Congenital Malformations (MCMs)

Observational1,178 targetStarted 2021-09Completion 2031-011 site · United StatesBiogen